First-in-human, randomized dose-escalation study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of PF-06480605 in healthy subjects.
Human genetic, tissue expression, proteomics, transcriptomics, and nonclinical studies implicate tumor necrosis factor α-like ligand 1A (TL1A) as a novel target in inflammatory bowel disease (IBD). PF-06480605, a fully human immunoglobulin G1 monoclonal antibody, targets TL1A. This first-in-human, Phase 1, dose-escalation study assessed safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of intravenous (IV) and subcutaneous (SC) PF-06480605 in healthy subjects (NCT01989143). Ninety-two subjects were randomized to single ascending doses (SAD): PF-06480605 1 mg, 3 mg, 10 mg, 30 mg, 100 mg, 300 mg, 600 mg, or 800 mg IV, or multiple ascending doses (MAD): PF-06480605 3x500 mg IV, or 3x30 mg, 3x100 mg, or 3x300 mg SC every 2 weeks for 3 doses, or placebo. Safety, tolerability, pharmacokinetics, immunogenicity profiles, and total TL1A, anti-drug antibody (ADA), and neutralizing antibody (NAb) levels, were assessed at pre-determined times. PF-06480605 SAD up to 800 mg IV and MAD up to 300 mg x3 SC and 500 mg x3 IV were well tolerated. Overall, there were 45 and 44 treatment-emergent adverse events in SAD and MAD cohorts, respectively, and no deaths or serious adverse events. PF-06480605 exposure generally increased dose-dependently. ADA and NAb levels did not impact safety, pharmacokinetics, or pharmacodynamics at higher doses. Target engagement was demonstrated through dose-dependent differences in serum total soluble TL1A concentrations for PF-06480605 vs placebo cohorts. PF-06480605 was generally well tolerated, and binding of soluble TL1A was maintained throughout the dose interval, supporting further study of PF-06480605 in patients with IBD and other inflammatory conditions.